Genecast Group Inc.

As a Leading Oncology Diagnostic Solution Provider

Genecast is offering from companion diagnostics to encompass prognosis, monitoring, early screening, and beyond.

As a Leading Oncology Diagnostic Solution Provider

Genecast is offering from companion diagnostics to encompass prognosis, monitoring, early screening, and beyond.

WE PROVIDE PRECISION TESTING KITS AND DIAGNOSTICS SERVICES GLOBALLY

Patient

Diagnosis and Treatment & Drug Supply

Diagnostics for personalized treatment
Result interpretation & professional consulting
Treatment matching

Doctors

Clinician

Clinical decision-making support
Clinical research support
Patient management

Pharmaceutical Plants

Data Support

Biomarker discovery
Patient profiling & sub-typing
Multi-omics & pharmaconomics research

Hospitals

Infrastructure & Platform Development

Clinical decision-making support
Treatment guidance based on molecular profiling
Patient communication & management

Ongoing clinical studies

EVIDENCE

FOCUS-C, LUNGCA

CAREMЕ, APEX

Testing volume

>
400,000

Patients

>
100,000

Physicians

>
8,000

Gross floor area

>
5,000

Hospitals

>
800

*By June 9，2025

Our Products & Services

Genecast Focus

Pan-cancer

Genecast HRD

Ovarian cancer, breast cancer, prostate cancer, pancreatic cancer

Genecast THEMIS

Early screening

Genecast Comprehensive

Pan-solid tumor

Genecast MRD MinerVa Prime

Pan-solid tumor

Select Country / Region

Singapore

China

Launching soon ! ...

All In One (AIO) Fully Automated System

Our Partners

Genecast News

June 03 , 2025 ASCO 2025 | A Quick Guide to Genecast's Multiple Research Highlights

Genecast was selected for presentation with three collaborative studies with clinical experts, selected for presentation at this year's meeting.

March30

2025

LUNGCA Study: West China Hospital's Team with Genecast Demonstrates ctDNA-Based Precision Management for Postoperative NSCLC Patients

February27

2025

Genecast Biotechnology's DNA & RNA co-sequencing Companion Diagnostic Kit Granted NMPA Medical Device Registration Certificate!

February11

2025

GCTSEQ-2000 Gene Sequencer Granted Medical Device Registration Certificate by China's NMPA!

September20

2024

Now Available | Genecast MRD MinerVa Prime for Clinical Use

Genecast Publications

June 03, 2025

Quantitative and dynamic ctDNA as a biomarker of response and survival in lung squamous cancer patients receiving immunochemotherapy or chemotherapy alone

May 31, 2025

Multi-omics analysis identifies different molecular subtypes with unique outcomes in early-stage poorly differentiated lung adenocarcinoma

March 25, 2025

Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)

February 27, 2025

An Expanding Universe of Mutational Signatures and Its Rapid Evolution in Single-Stranded RNA Viruse

January 31, 2025

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study

December 27, 2024

Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations

December 25, 2024

AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC

November 25, 2024

Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial

August 23, 2024

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study

June 28, 2024

Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma

Share ：

#02-01/02, The Kendall, 50 Science Park Road. Singapore Science Park 2, Singapore 117406

Tel: +65 6047 0252 ; Email: info@genecast.com.sg

Design by Bobrand

TOP